Mineralys therapeutics inc MLYS.US Overview Analysis
MLYS AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
MLYS Current Performance
2.07%
Mineralys therapeutics inc
0.23%
Avg of Sector
0.43%
S&P500
Top 10 High Relevance to MLYS
- RAPP Rapport therapeutics incValue -Trend 3Swing Trading 5Whale Interest 2Dividend 1See more
MLYS Profile
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.